CL2016002809A1 - Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión. - Google Patents
Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión.Info
- Publication number
- CL2016002809A1 CL2016002809A1 CL2016002809A CL2016002809A CL2016002809A1 CL 2016002809 A1 CL2016002809 A1 CL 2016002809A1 CL 2016002809 A CL2016002809 A CL 2016002809A CL 2016002809 A CL2016002809 A CL 2016002809A CL 2016002809 A1 CL2016002809 A1 CL 2016002809A1
- Authority
- CL
- Chile
- Prior art keywords
- gpr40
- retinopathy
- neuropathy
- heterocycles
- atherosclerosis
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 206010020772 Hypertension Diseases 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 208000017442 Retinal disease Diseases 0.000 title abstract 2
- 206010038923 Retinopathy Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 2
- 201000001119 neuropathy Diseases 0.000 title abstract 2
- 230000007823 neuropathy Effects 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína G 40 (GPR40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989651P | 2014-05-07 | 2014-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002809A1 true CL2016002809A1 (es) | 2017-03-24 |
Family
ID=53181359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002809A CL2016002809A1 (es) | 2014-05-07 | 2016-11-07 | Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión. |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9873679B2 (es) |
| EP (1) | EP3140296B1 (es) |
| JP (1) | JP6483156B2 (es) |
| KR (1) | KR102336370B1 (es) |
| CN (1) | CN106458976B (es) |
| AR (1) | AR100328A1 (es) |
| AU (1) | AU2015256120B2 (es) |
| BR (1) | BR112016024936A2 (es) |
| CA (1) | CA2948161C (es) |
| CL (1) | CL2016002809A1 (es) |
| CY (1) | CY1120340T1 (es) |
| DK (1) | DK3140296T3 (es) |
| EA (1) | EA033250B1 (es) |
| ES (1) | ES2674531T3 (es) |
| HR (1) | HRP20180641T1 (es) |
| HU (1) | HUE039288T2 (es) |
| IL (1) | IL248668B (es) |
| MA (1) | MA39427B1 (es) |
| MX (1) | MX378160B (es) |
| MY (1) | MY181959A (es) |
| NZ (1) | NZ727146A (es) |
| PE (1) | PE20161363A1 (es) |
| PH (1) | PH12016502034B1 (es) |
| PL (1) | PL3140296T3 (es) |
| PT (1) | PT3140296T (es) |
| RS (1) | RS57170B1 (es) |
| SG (1) | SG11201609170UA (es) |
| SI (1) | SI3140296T1 (es) |
| SM (1) | SMT201800342T1 (es) |
| TN (1) | TN2016000444A1 (es) |
| TR (1) | TR201809633T4 (es) |
| TW (1) | TWI659951B (es) |
| WO (1) | WO2015171722A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015256038B2 (en) * | 2014-05-07 | 2019-07-11 | Bristol-Myers Squibb Company | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes |
| DK3140296T3 (en) * | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
| WO2018049324A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Monocyclic compounds useful as gpr120 modulators |
| EP3509588B1 (en) | 2016-09-12 | 2023-06-07 | Integral Health,Inc. | Bicyclic compounds useful as gpr120 modulators |
| JPWO2018181847A1 (ja) * | 2017-03-31 | 2020-03-05 | 武田薬品工業株式会社 | 芳香環化合物 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN110772636B (zh) * | 2017-08-21 | 2021-03-16 | 武汉大学 | Gpr31抑制剂在制备治疗心脏缺血再灌注损伤及相关疾病药物中的应用 |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US11919879B2 (en) | 2021-06-16 | 2024-03-05 | Celgene Corporation | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases |
| CN116283699B (zh) * | 2023-03-02 | 2025-02-11 | 遵义医科大学 | 一种合成氟烷基取代的吡咯烷的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| KR20120104534A (ko) * | 2009-10-06 | 2012-09-21 | 브리스톨-마이어스 스큅 컴퍼니 | 피롤리딘 ｇｐｒ40 조절제 |
| US7939569B1 (en) * | 2009-12-01 | 2011-05-10 | Hoffmann-La Roche Inc. | Aniline analogs as glycogen synthase activators |
| GB2498976A (en) * | 2012-02-01 | 2013-08-07 | Prosidion Ltd | GPR119 agonists useful in the treatment of type II diabetes |
| EP2880034B1 (en) | 2012-08-01 | 2016-06-22 | Bristol-Myers Squibb Company | Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor |
| CA2891535A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
| BR112015010649A2 (pt) * | 2012-11-16 | 2017-07-11 | Bristol Myers Squibb Co | moduladores de gpr40 à base de pirrolidina |
| WO2014078610A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
| JP6322204B2 (ja) | 2012-11-16 | 2018-05-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ジヒドロピラゾールのｇｐｒ４０モジュレーター |
| DK3140296T3 (en) * | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
| US10301260B2 (en) | 2014-05-07 | 2019-05-28 | Bristol-Myers Squibb Company | Pyrrolidine GPR40 modulators |
| CN106456536B (zh) | 2014-05-07 | 2020-05-12 | 克罗马药品股份有限公司 | 水性眼用溶液和治疗干眼综合征的方法 |
-
2015
- 2015-05-06 DK DK15723095.4T patent/DK3140296T3/en active
- 2015-05-06 CN CN201580022579.4A patent/CN106458976B/zh active Active
- 2015-05-06 AR ARP150101379A patent/AR100328A1/es unknown
- 2015-05-06 PL PL15723095T patent/PL3140296T3/pl unknown
- 2015-05-06 MA MA39427A patent/MA39427B1/fr unknown
- 2015-05-06 SG SG11201609170UA patent/SG11201609170UA/en unknown
- 2015-05-06 NZ NZ727146A patent/NZ727146A/en unknown
- 2015-05-06 TR TR2018/09633T patent/TR201809633T4/tr unknown
- 2015-05-06 HR HRP20180641TT patent/HRP20180641T1/hr unknown
- 2015-05-06 US US14/705,524 patent/US9873679B2/en active Active
- 2015-05-06 MY MYPI2016704054A patent/MY181959A/en unknown
- 2015-05-06 EA EA201692037A patent/EA033250B1/ru not_active IP Right Cessation
- 2015-05-06 SI SI201530232T patent/SI3140296T1/en unknown
- 2015-05-06 MX MX2016013801A patent/MX378160B/es unknown
- 2015-05-06 KR KR1020167033863A patent/KR102336370B1/ko active Active
- 2015-05-06 TW TW104114493A patent/TWI659951B/zh active
- 2015-05-06 CA CA2948161A patent/CA2948161C/en active Active
- 2015-05-06 HU HUE15723095A patent/HUE039288T2/hu unknown
- 2015-05-06 AU AU2015256120A patent/AU2015256120B2/en active Active
- 2015-05-06 PT PT157230954T patent/PT3140296T/pt unknown
- 2015-05-06 EP EP15723095.4A patent/EP3140296B1/en active Active
- 2015-05-06 SM SM20180342T patent/SMT201800342T1/it unknown
- 2015-05-06 JP JP2016566651A patent/JP6483156B2/ja active Active
- 2015-05-06 WO PCT/US2015/029409 patent/WO2015171722A1/en not_active Ceased
- 2015-05-06 PE PE2016002178A patent/PE20161363A1/es unknown
- 2015-05-06 TN TN2016000444A patent/TN2016000444A1/en unknown
- 2015-05-06 RS RS20180504A patent/RS57170B1/sr unknown
- 2015-05-06 BR BR112016024936A patent/BR112016024936A2/pt not_active Application Discontinuation
- 2015-05-06 ES ES15723095.4T patent/ES2674531T3/es active Active
-
2016
- 2016-10-12 PH PH12016502034A patent/PH12016502034B1/en unknown
- 2016-11-01 IL IL248668A patent/IL248668B/en active IP Right Grant
- 2016-11-07 CL CL2016002809A patent/CL2016002809A1/es unknown
-
2017
- 2017-12-13 US US15/840,198 patent/US20180099949A1/en not_active Abandoned
-
2018
- 2018-05-23 CY CY20181100547T patent/CY1120340T1/el unknown
- 2018-12-06 US US16/211,848 patent/US10717725B2/en active Active
-
2020
- 2020-06-08 US US16/895,058 patent/US20200299267A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002809A1 (es) | Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión. | |
| CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
| CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| UY34832A (es) | TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda) | |
| CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
| GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| MX382815B (es) | Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas. | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| CL2015002855A1 (es) | Derivados de oxopiridina sustituida. | |
| DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| CL2015003314A1 (es) | Inhibidores de acc y usos de los mismos | |
| UY34833A (es) | Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano RORy | |
| CR20170076A (es) | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| MX378158B (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139). | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| CY1125153T1 (el) | Νεα ετεροκυκλικα αντiοιστρογονα | |
| UY35571A (es) | (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles como agonistas del receptor cannabinoide 2 (cb2) | |
| CY1119907T1 (el) | Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου | |
| MX2016010529A (es) | Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6). | |
| MX2016011535A (es) | Ureas asimetricas p-sustituidas y usos medicos de las mismas. |